Annals of the New York Academy of Sciences

Cover image for Annals of the New York Academy of Sciences

December 2000

Volume 922 THE CAMPTOTHECINS: UNFOLDING THEIR ANTICANCER POTENTIAL

Pages xi–xii, 1–360

  1. Frontmatter

    1. Top of page
    2. Frontmatter
    3. Keynote Lecture
    4. The Camptothecins: Unfolding Their Anticancer Potential: Part I. Mechanism of Action of Camptothecins
    5. The Camptothecins: Unfolding Their Anticancer Potential: Part II. Mechanism-Based Design and Synthesis of Novel Camptothecins
    6. The Camptothecins: Unfolding Their Anticancer Potential: Part III. Novel Topoisomerase I Inhibitors
    7. The Camptothecins: Unfolding Their Anticancer Potential: Part IV. New Camptothecin Derivatives and Formulations
    8. The Camptothecins: Unfolding Their Anticancer Potential: Part V. Pharmacology
    9. The Camptothecins: Unfolding Their Anticancer Potential: Part VI. Clinical Trials I, Newer Analogues
    10. The Camptothecins: Unfolding Their Anticancer Potential: Part VII. Clinical Trials II, Combination Therapy
    11. The Camptothecins: Unfolding Their Anticancer Potential: Part VIII. Poster Papers
    12. The Camptothecins: Unfolding Their Anticancer Potential: Part IX. Concluding Remarks
    1. Introduction (pages xi–xii)

      JOACHIM G. LIEHR and BEPPINO GIOVANELLA

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07019.x

  2. Keynote Lecture

    1. Top of page
    2. Frontmatter
    3. Keynote Lecture
    4. The Camptothecins: Unfolding Their Anticancer Potential: Part I. Mechanism of Action of Camptothecins
    5. The Camptothecins: Unfolding Their Anticancer Potential: Part II. Mechanism-Based Design and Synthesis of Novel Camptothecins
    6. The Camptothecins: Unfolding Their Anticancer Potential: Part III. Novel Topoisomerase I Inhibitors
    7. The Camptothecins: Unfolding Their Anticancer Potential: Part IV. New Camptothecin Derivatives and Formulations
    8. The Camptothecins: Unfolding Their Anticancer Potential: Part V. Pharmacology
    9. The Camptothecins: Unfolding Their Anticancer Potential: Part VI. Clinical Trials I, Newer Analogues
    10. The Camptothecins: Unfolding Their Anticancer Potential: Part VII. Clinical Trials II, Combination Therapy
    11. The Camptothecins: Unfolding Their Anticancer Potential: Part VIII. Poster Papers
    12. The Camptothecins: Unfolding Their Anticancer Potential: Part IX. Concluding Remarks
    1. Mechanism of Action of Camptothecin (pages 1–10)

      LEROY F. LIU, SHYAMAL D. DESAI, TSAI-KUN LI, YONG MAO, MEI SUN and SAI-PENG SIM

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07020.x

  3. The Camptothecins: Unfolding Their Anticancer Potential: Part I. Mechanism of Action of Camptothecins

    1. Top of page
    2. Frontmatter
    3. Keynote Lecture
    4. The Camptothecins: Unfolding Their Anticancer Potential: Part I. Mechanism of Action of Camptothecins
    5. The Camptothecins: Unfolding Their Anticancer Potential: Part II. Mechanism-Based Design and Synthesis of Novel Camptothecins
    6. The Camptothecins: Unfolding Their Anticancer Potential: Part III. Novel Topoisomerase I Inhibitors
    7. The Camptothecins: Unfolding Their Anticancer Potential: Part IV. New Camptothecin Derivatives and Formulations
    8. The Camptothecins: Unfolding Their Anticancer Potential: Part V. Pharmacology
    9. The Camptothecins: Unfolding Their Anticancer Potential: Part VI. Clinical Trials I, Newer Analogues
    10. The Camptothecins: Unfolding Their Anticancer Potential: Part VII. Clinical Trials II, Combination Therapy
    11. The Camptothecins: Unfolding Their Anticancer Potential: Part VIII. Poster Papers
    12. The Camptothecins: Unfolding Their Anticancer Potential: Part IX. Concluding Remarks
    1. Dependence of Anticancer Activity of Camptothecins on Maintaining Their Lactone Function (pages 27–35)

      B. C. GIOVANELLA, N. HARRIS, J. MENDOZA, Z. CAO, J. LIEHR and J. S. STEHLIN

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07022.x

    2. Mechanisms of Resistance to Camptothecins (pages 46–55)

      AHAMED SALEEM, TROY K. EDWARDS, ZESHAAN RASHEED and ERIC H. RUBIN

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07024.x

  4. The Camptothecins: Unfolding Their Anticancer Potential: Part II. Mechanism-Based Design and Synthesis of Novel Camptothecins

    1. Top of page
    2. Frontmatter
    3. Keynote Lecture
    4. The Camptothecins: Unfolding Their Anticancer Potential: Part I. Mechanism of Action of Camptothecins
    5. The Camptothecins: Unfolding Their Anticancer Potential: Part II. Mechanism-Based Design and Synthesis of Novel Camptothecins
    6. The Camptothecins: Unfolding Their Anticancer Potential: Part III. Novel Topoisomerase I Inhibitors
    7. The Camptothecins: Unfolding Their Anticancer Potential: Part IV. New Camptothecin Derivatives and Formulations
    8. The Camptothecins: Unfolding Their Anticancer Potential: Part V. Pharmacology
    9. The Camptothecins: Unfolding Their Anticancer Potential: Part VI. Clinical Trials I, Newer Analogues
    10. The Camptothecins: Unfolding Their Anticancer Potential: Part VII. Clinical Trials II, Combination Therapy
    11. The Camptothecins: Unfolding Their Anticancer Potential: Part VIII. Poster Papers
    12. The Camptothecins: Unfolding Their Anticancer Potential: Part IX. Concluding Remarks
  5. The Camptothecins: Unfolding Their Anticancer Potential: Part III. Novel Topoisomerase I Inhibitors

    1. Top of page
    2. Frontmatter
    3. Keynote Lecture
    4. The Camptothecins: Unfolding Their Anticancer Potential: Part I. Mechanism of Action of Camptothecins
    5. The Camptothecins: Unfolding Their Anticancer Potential: Part II. Mechanism-Based Design and Synthesis of Novel Camptothecins
    6. The Camptothecins: Unfolding Their Anticancer Potential: Part III. Novel Topoisomerase I Inhibitors
    7. The Camptothecins: Unfolding Their Anticancer Potential: Part IV. New Camptothecin Derivatives and Formulations
    8. The Camptothecins: Unfolding Their Anticancer Potential: Part V. Pharmacology
    9. The Camptothecins: Unfolding Their Anticancer Potential: Part VI. Clinical Trials I, Newer Analogues
    10. The Camptothecins: Unfolding Their Anticancer Potential: Part VII. Clinical Trials II, Combination Therapy
    11. The Camptothecins: Unfolding Their Anticancer Potential: Part VIII. Poster Papers
    12. The Camptothecins: Unfolding Their Anticancer Potential: Part IX. Concluding Remarks
    1. Homocamptothecins: E-Ring Modified CPT Analogues (pages 100–111)

      OLIVIER LAVERGNE, DANIELE DEMARQUAY, PHILIP G. KASPRZYK and DENNIS C.H. BIGG

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07029.x

  6. The Camptothecins: Unfolding Their Anticancer Potential: Part IV. New Camptothecin Derivatives and Formulations

    1. Top of page
    2. Frontmatter
    3. Keynote Lecture
    4. The Camptothecins: Unfolding Their Anticancer Potential: Part I. Mechanism of Action of Camptothecins
    5. The Camptothecins: Unfolding Their Anticancer Potential: Part II. Mechanism-Based Design and Synthesis of Novel Camptothecins
    6. The Camptothecins: Unfolding Their Anticancer Potential: Part III. Novel Topoisomerase I Inhibitors
    7. The Camptothecins: Unfolding Their Anticancer Potential: Part IV. New Camptothecin Derivatives and Formulations
    8. The Camptothecins: Unfolding Their Anticancer Potential: Part V. Pharmacology
    9. The Camptothecins: Unfolding Their Anticancer Potential: Part VI. Clinical Trials I, Newer Analogues
    10. The Camptothecins: Unfolding Their Anticancer Potential: Part VII. Clinical Trials II, Combination Therapy
    11. The Camptothecins: Unfolding Their Anticancer Potential: Part VIII. Poster Papers
    12. The Camptothecins: Unfolding Their Anticancer Potential: Part IX. Concluding Remarks
    1. Structure-Activity Relationship of Alkyl Camptothecin Esters (pages 122–135)

      ZHISONG CAO, PANAYOTIS FANTAZIS, JOHN MENDOZA, JANET EARLY, ANTHONY KOZIELSKI, NICK HARRIS, DANA VARDEMAN, JOACHIM LIEHR, JOHN S. STEHLIN and BEPPINO GIOVANELLA

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07031.x

    2. Conjugation of Camptothecins to Poly-(l-Glutamic Acid) (pages 136–150)

      JACK W. SINGER, PETER DE VRIES, RAMA BHATT, JOHN TULINSKY, PETER KLEIN, CHUN LI, LUKA MILAS, ROBERT A. LEWIS and SIDNEY WALLACE

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07032.x

    3. 9-Nitrocamptothecin Liposome Aerosol Treatment of Human Cancer Subcutaneous Xenografts and Pulmonary Cancer Metastases in Mice (pages 151–163)

      VERNON KNIGHT, EUGENIE S. KLEINERMAN, J. CLIFFORD WALDREP, BEPPINO C. GIOVANELLA, BRIAN E. GILBERT and NADEZHDA V. KOSHKINA

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07033.x

    4. Modified Lactone/Carboxylate Salt Equilibria in Vivo by Liposomal Delivery of 9-Nitro-Camptothecin (pages 164–174)

      DIANA S-L. CHOW, LING GONG, MICHAEL D. WOLFE and BEPPINO C. GIOVANELLA

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07034.x

    5. New Analogues of Camptothecins: Activity and Resistance (pages 175–177)

      EPIE BOVEN, ANNEMARIE H. Van HATTUM, ILSE HOOGSTEEN, HENNIE M.M. SCHLÜPER and H. M. PINEDO

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07035.x

    6. Intraperitoneal Topoisomerase-I Inhibitors: Preliminary Findings with 9-Aminocamptothecin (pages 178–187)

      FRANCO MUGGIA, LEONARD LIEBES, MILAN POTMESIL, ANNE HAMILTON, HOWARD HOCHSTER, GILA HORNREICH, JOAN SORICH, ANDREA DOWNEY and HEATHER WASSERSTROM

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07036.x

  7. The Camptothecins: Unfolding Their Anticancer Potential: Part V. Pharmacology

    1. Top of page
    2. Frontmatter
    3. Keynote Lecture
    4. The Camptothecins: Unfolding Their Anticancer Potential: Part I. Mechanism of Action of Camptothecins
    5. The Camptothecins: Unfolding Their Anticancer Potential: Part II. Mechanism-Based Design and Synthesis of Novel Camptothecins
    6. The Camptothecins: Unfolding Their Anticancer Potential: Part III. Novel Topoisomerase I Inhibitors
    7. The Camptothecins: Unfolding Their Anticancer Potential: Part IV. New Camptothecin Derivatives and Formulations
    8. The Camptothecins: Unfolding Their Anticancer Potential: Part V. Pharmacology
    9. The Camptothecins: Unfolding Their Anticancer Potential: Part VI. Clinical Trials I, Newer Analogues
    10. The Camptothecins: Unfolding Their Anticancer Potential: Part VII. Clinical Trials II, Combination Therapy
    11. The Camptothecins: Unfolding Their Anticancer Potential: Part VIII. Poster Papers
    12. The Camptothecins: Unfolding Their Anticancer Potential: Part IX. Concluding Remarks
    1. Transport of Topoisomerase I Inhibitors by the Breast Cancer Resistance Protein: Potential Clinical Implications (pages 188–194)

      JAN H.M. SCHELLENS, MARC MALIEPAARD, RIK J. SCHEPER, GEORGE L. SCHEFFER, JOHAN W. JONKER, JOHAN W. SMIT, JOS H. BEIJNEN and ALFRED H. SCHINKEL

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07037.x

    2. Pharmacokinetics of Orally Administered Camptothecins (pages 195–204)

      ELORA GUPTA, VIRAL VYAS, FARHEENA AHMED, PATRICK SINKO, THOMAS COOK and ERIC RUBIN

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07038.x

    3. Metabolism of CPT-11: Impact on Activity (pages 205–215)

      LAURENT P. RIVORY

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07039.x

    4. Pharmacology of Camptothecin Esters (pages 216–223)

      JOACHIM G. LIEHR, NICK J. HARRIS, JOHN MENDOZA, AHMED E. AHMED and BEPPINO C. GIOVANELLA

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07040.x

  8. The Camptothecins: Unfolding Their Anticancer Potential: Part VI. Clinical Trials I, Newer Analogues

    1. Top of page
    2. Frontmatter
    3. Keynote Lecture
    4. The Camptothecins: Unfolding Their Anticancer Potential: Part I. Mechanism of Action of Camptothecins
    5. The Camptothecins: Unfolding Their Anticancer Potential: Part II. Mechanism-Based Design and Synthesis of Novel Camptothecins
    6. The Camptothecins: Unfolding Their Anticancer Potential: Part III. Novel Topoisomerase I Inhibitors
    7. The Camptothecins: Unfolding Their Anticancer Potential: Part IV. New Camptothecin Derivatives and Formulations
    8. The Camptothecins: Unfolding Their Anticancer Potential: Part V. Pharmacology
    9. The Camptothecins: Unfolding Their Anticancer Potential: Part VI. Clinical Trials I, Newer Analogues
    10. The Camptothecins: Unfolding Their Anticancer Potential: Part VII. Clinical Trials II, Combination Therapy
    11. The Camptothecins: Unfolding Their Anticancer Potential: Part VIII. Poster Papers
    12. The Camptothecins: Unfolding Their Anticancer Potential: Part IX. Concluding Remarks
    1. The Clinical Development of 9-Aminocamptothecin (pages 224–236)

      CHRIS H. TAKIMOTO and REBECCA THOMAS

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07041.x

    2. Alternative Administration of Camptothecin Analogues (pages 237–246)

      C. F. VERSCHRAEGEN, K. JAECKLE, B. GIOVANELLA, V. KNIGHT and B. E. GILBERT

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07042.x

    3. DX-8951f: Summary of Phase I Clinical Trials (pages 260–273)

      R. DE JAGER, P. CHEVERTON, K. TAMANOI, J. COYLE, M. DUCHARME, N. SAKAMOTO, M. SATOMI, M. SUZUKI and THE DX-8951F INVESTIGATORS

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07044.x

  9. The Camptothecins: Unfolding Their Anticancer Potential: Part VII. Clinical Trials II, Combination Therapy

    1. Top of page
    2. Frontmatter
    3. Keynote Lecture
    4. The Camptothecins: Unfolding Their Anticancer Potential: Part I. Mechanism of Action of Camptothecins
    5. The Camptothecins: Unfolding Their Anticancer Potential: Part II. Mechanism-Based Design and Synthesis of Novel Camptothecins
    6. The Camptothecins: Unfolding Their Anticancer Potential: Part III. Novel Topoisomerase I Inhibitors
    7. The Camptothecins: Unfolding Their Anticancer Potential: Part IV. New Camptothecin Derivatives and Formulations
    8. The Camptothecins: Unfolding Their Anticancer Potential: Part V. Pharmacology
    9. The Camptothecins: Unfolding Their Anticancer Potential: Part VI. Clinical Trials I, Newer Analogues
    10. The Camptothecins: Unfolding Their Anticancer Potential: Part VII. Clinical Trials II, Combination Therapy
    11. The Camptothecins: Unfolding Their Anticancer Potential: Part VIII. Poster Papers
    12. The Camptothecins: Unfolding Their Anticancer Potential: Part IX. Concluding Remarks
    1. Cellular and Molecular Responses to Topoisomerase I Poisons: Exploiting Synergy for Improved Radiotherapy (pages 274–292)

      SHIGEKI MIYAMOTO, TONY T. HUANG, SHELLY WUERZBERGER-DAVIS, WILLIAM G. BORNMANN, JOHN J. PINK, COLLEEN TAGLIARINO, TIMOTHY J. KINSELLA and DAVID A. BOOTHMAN

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07045.x

    2. In Vitro Antitumor Activity of 9-Nitro-Camptothecin as a Single Agent and in Combination with other Antitumor Drugs (pages 293–297)

      RALPH J. BERNACKI, PAULA PERA, PETER GAMBACORTA, YSEULT BRUN and WILLIAM R. GRECO

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07046.x

    3. p53 and p21 Are Major Cellular Determinants for DNA Topoisomerase I-Mediated Radiation Sensitization in Mammalian Cells (pages 298–300)

      ALLAN Y. CHEN, a, c 1 PAUL B. SCRUGGS, a LING GENG, a MACE L. ROTHENBERG and b DENNIS E. HALLAHAN a

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07047.x

  10. The Camptothecins: Unfolding Their Anticancer Potential: Part VIII. Poster Papers

    1. Top of page
    2. Frontmatter
    3. Keynote Lecture
    4. The Camptothecins: Unfolding Their Anticancer Potential: Part I. Mechanism of Action of Camptothecins
    5. The Camptothecins: Unfolding Their Anticancer Potential: Part II. Mechanism-Based Design and Synthesis of Novel Camptothecins
    6. The Camptothecins: Unfolding Their Anticancer Potential: Part III. Novel Topoisomerase I Inhibitors
    7. The Camptothecins: Unfolding Their Anticancer Potential: Part IV. New Camptothecin Derivatives and Formulations
    8. The Camptothecins: Unfolding Their Anticancer Potential: Part V. Pharmacology
    9. The Camptothecins: Unfolding Their Anticancer Potential: Part VI. Clinical Trials I, Newer Analogues
    10. The Camptothecins: Unfolding Their Anticancer Potential: Part VII. Clinical Trials II, Combination Therapy
    11. The Camptothecins: Unfolding Their Anticancer Potential: Part VIII. Poster Papers
    12. The Camptothecins: Unfolding Their Anticancer Potential: Part IX. Concluding Remarks
    1. The Homocamptothecin, BN 80927, Is a Potent Topoisomerase I Poison and Topoisomerase II Catalytic Inhibitor (pages 301–302)

      DANIÈLE DEMARQUAY, HÉLÈNE COULOMB, MARION HUCHET, LAURENCE LESUEUR-GINOT, JOSÉ CAMARA, OLIVIER LAVERGNE and DENNIS BIGG

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07048.x

    2. The Dual Topoisomerase Inhibitor, BN 80927, Is Highly Potent against Cell Proliferation and Tumor Growth (pages 303–305)

      MARION HUCHET, DANIÈLE DEMARQUAY, HÉLÈNE COULOMB, PHILIP KASPRZYK, MARK CARLSON, JEFFREY LAUER, OLIVIER La VERGNE and DENNIS BIGG

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07049.x

    3. Ubiquitin, SUMO-1, and UCRP in Camptothecin Sensitivity and Resistance (pages 306–308)

      SHYAMAL D. DESAI, YONG MAO, MEI SUN, TSAI-KUN LI, JIAXI WU and LEROY F. LIU

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07050.x

    4. Kinetics of in Vitro Hydrolysis of Homocamptothecins As Measured by Fluorescence (pages 314–316)

      D. CHAUVIER, I. CHOURPA, D. C.H. BIGG and M. MANFAIT

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07052.x

    5. The Combinatorial Synthesis of Racemic Homosilatecan Libraries via a Cascade Radical Annulation (pages 317–319)

      WU DU, ANA E. GABARDA, DAVID BOM and DENNIS P. CURRAN

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07053.x

    6. Preclinical and Phase I Clinical Studies with Ckd-602, a Novel Camptothecin Derivative (pages 324–325)

      J. H. LEE, J. M. LEE, K. H. LIM, J. K. KIM, S. K. AHN, Y. J. BANG and C. I. HONG

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07055.x

    7. Improvement of Therapeutic Index of Low-Dose Topotecan Delivered per os (pages 330–333)

      GRAZIELLA PRATESI, MICHELANDREA DE CESARE and FRANCO ZUNINO

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07057.x

    8. Rapid Chromatin Reorganization Induced by Topoisomerase I-Mediated DNA Damage (pages 340–342)

      MEI SUN, PU DUANN, CHIN-TAI LIN, HUI ZHANG and LEROY F. LIU

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07059.x

    9. Phase I Study of 9-Nitro-20(S)-Camptothecin in Combination with Cisplatin for Patients with Advanced Malignancies (pages 345–348)

      C. F. VERSCHRAEGEN, M. VINCENT, J. L. ABBRUZZESE, D. SIEGLER, J. J. KAVANAGH, E. LOYER, A. P. KUDELKA and E. RUBIN

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07061.x

    10. Phase II Study of Intravenous DX-8951f in Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane, and Topotecan (pages 349–351)

      C. F. VERSCHRAEGEN, C. LEVENBACK, M. VINCENT, J. WOLF, M. BEVERS, E. LOYER, A. P. KUDELKA and J. J. KAVANAGH

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07062.x

    11. Feasibility, Phase I, and Pharmacological Study of Aerosolized Liposomal 9-Nitro-20(S)-Camptothecin in Patients with Advanced Malignancies in the Lungs (pages 352–354)

      C. F. VERSCHRAEGEN, B. E. GILBERT, A. J. HUARINGA, R. NEWMAN, N. HARRIS, F. J. LEYVA, L. KEUS, K. CAMPBELL, T. NELSON-TAYLOR and V. KNIGHT

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07063.x

  11. The Camptothecins: Unfolding Their Anticancer Potential: Part IX. Concluding Remarks

    1. Top of page
    2. Frontmatter
    3. Keynote Lecture
    4. The Camptothecins: Unfolding Their Anticancer Potential: Part I. Mechanism of Action of Camptothecins
    5. The Camptothecins: Unfolding Their Anticancer Potential: Part II. Mechanism-Based Design and Synthesis of Novel Camptothecins
    6. The Camptothecins: Unfolding Their Anticancer Potential: Part III. Novel Topoisomerase I Inhibitors
    7. The Camptothecins: Unfolding Their Anticancer Potential: Part IV. New Camptothecin Derivatives and Formulations
    8. The Camptothecins: Unfolding Their Anticancer Potential: Part V. Pharmacology
    9. The Camptothecins: Unfolding Their Anticancer Potential: Part VI. Clinical Trials I, Newer Analogues
    10. The Camptothecins: Unfolding Their Anticancer Potential: Part VII. Clinical Trials II, Combination Therapy
    11. The Camptothecins: Unfolding Their Anticancer Potential: Part VIII. Poster Papers
    12. The Camptothecins: Unfolding Their Anticancer Potential: Part IX. Concluding Remarks
    1. Concluding Remarks (page 360)

      CLAIRE VERSCHRAEGEN

      Article first published online: 25 JAN 2006 | DOI: 10.1111/j.1749-6632.2000.tb07065.x

SEARCH

SEARCH BY CITATION